Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2013, Pages 165-172

  Matias, Bruna F ^a   de Oliveira, Tânia M ^a   Rodrigues, Cláudia M ^a   Abdalla, Douglas R ^a   Montes, Letícia ^a   Murta, Eddie F C ^a,b   Michelin, Márcia A ^a,c  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^b Discipline of Gynaecology and Obstetrics   (Brazil)

^c Discipline of Immunology   (Brazil)

Author keywords

Cancer; Dendritic cells; Immune response; Immunotherapy

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MELANOMA; METASTASIS; NATURAL KILLER CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL; UTERINE CERVIX CANCER; VAGINA CANCER; VAGINA METASTASIS; VAGINAL MELANOMA; VITILIGO;

EID: 84880829825     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S12268     Document Type: Article

References (28)

1. Dougan M, Dranoff G. Immune therapy for cancer. Ann Rev Immunol. 2009;27:83-117.
2. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-59.
3. Coca S, Perez-Piqueras J, Martinez D. et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320-8.
4. Ishigami S, Natsugoe S, Tokuda K, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett. 2000;159(1):103-8.
5. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516-21.
6. Enzler T, Gillessen S, Manis JP, et al. Deficiencies of GM-CSF and interferon-gamma link inflammation and cancer. J Exp Med. 2003;197(9): 1213-9.
7. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24-37.
8. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/ macrophage infiltration in tumours: modulators of angiogenesis. J Leukoc Biol. 2006;80(6):1183-96.
9. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503-10.
10. Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumour microenvironments and the progression of tumours. Clin Dev Immunol. 2012;2012:948098.
11. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene. 2000;19(56):6673-9.
12. Vari F, Hart DN. Loading DCs with Ag. Cytotherapy. 2004;6(2):111-21.
13. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med. 2007;39(6):679-89.
14. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments includ-ing vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009;58(3):317-24.
15. Rodrigues CM, Matias BF, Murta EFC, Michelin MA. The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. Clin Med Insights Oncol. 2011;5:107-15.
16. Soliman H. Developing an effective breast cancer vaccine. Cancer Control. 2010;17(3):183-90.
17. Ernstoff MS, Nair S, Bahnson RR, et al. A phase IA trial of sequential admin-istration recombinant DNA-produced interferons: combination recombinant interferon γ and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990;8:1637-49.
18. Shwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleu-kin (interleukin 2) and IFN-α2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009;15(15):4986-92.
19. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19(1):81-4.
20. Sun Y, Paschen A, Schadendorf D. Cell-based vaccination against melanoma-background, preliminary results, and perspective. J Mol Med (Berl). 1999;77(8):593-608.
21. Andreesen R, Scheibenbogen C, Brugger W, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood mono-cytes: a new approach to cancer immunotherapy. Cancer Res. 1990;50(23): 7450-6.
22. Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009;70(5):481-9.
23. Bennaceur K, Chapman J, Brikci-Nigassa L, Sanhadji K, Touraine JL, Portoukalian J. Dendritic cells dysfunction in tumour environment. Cancer Lett. 2008;272(2):186-96.
24. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12(3 Pt 1):878-87.
25. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296-306.
26. Mathis D, Benoist C. Back to central tolerance. Immunity. 2004;20:509-16.
27. Evel-Kabler K, Chen SY. Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol Ther. 2006;13(5):850-8.
28. Lokhov PG, Balashova EE. Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens. J Cancer. 2010;1:230-41.